AU2020366519B2 - Lipid nanoparticles and formulations thereof for CAR mRNA delivery - Google Patents
Lipid nanoparticles and formulations thereof for CAR mRNA deliveryInfo
- Publication number
- AU2020366519B2 AU2020366519B2 AU2020366519A AU2020366519A AU2020366519B2 AU 2020366519 B2 AU2020366519 B2 AU 2020366519B2 AU 2020366519 A AU2020366519 A AU 2020366519A AU 2020366519 A AU2020366519 A AU 2020366519A AU 2020366519 B2 AU2020366519 B2 AU 2020366519B2
- Authority
- AU
- Australia
- Prior art keywords
- lnp
- antigen
- mrna
- mol
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916942P | 2019-10-18 | 2019-10-18 | |
| US62/916,942 | 2019-10-18 | ||
| PCT/US2020/056255 WO2021077067A1 (en) | 2019-10-18 | 2020-10-19 | Lipid nanoparticles and formulations thereof for car mrna delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2026213957A Division AU2026213957A1 (en) | 2019-10-18 | 2026-08-04 | Lipid nanoparticles and formulations thereof for CAR mRNA delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020366519A1 AU2020366519A1 (en) | 2022-05-26 |
| AU2020366519B2 true AU2020366519B2 (en) | 2026-05-28 |
Family
ID=75538674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020366519A Active AU2020366519B2 (en) | 2019-10-18 | 2020-10-19 | Lipid nanoparticles and formulations thereof for CAR mRNA delivery |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220378700A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4045021A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7744687B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220084366A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114828837A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020366519B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3155075A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021077067A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117098541A (zh) | 2020-11-25 | 2023-11-21 | 阿卡格拉医药公司 | 用于递送核酸的脂质纳米粒及相关使用方法 |
| US20240298649A1 (en) * | 2021-06-14 | 2024-09-12 | Flagship Pioneering Innovations Vi, Llc | Modification of plant messenger packs |
| WO2023023055A1 (en) | 2021-08-16 | 2023-02-23 | Renagade Therapeutics Management Inc. | Compositions and methods for optimizing tropism of delivery systems for rna |
| CN115724806B (zh) * | 2021-08-25 | 2025-07-01 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| WO2023044343A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
| TW202328067A (zh) | 2021-09-14 | 2023-07-16 | 美商雷納嘉德醫療管理公司 | 環狀脂質及其使用方法 |
| CA3233490A1 (en) * | 2021-09-28 | 2023-04-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for t cell targeted delivery of therapeutic agents |
| EP4408437A4 (en) * | 2021-10-01 | 2025-08-27 | Univ Pennsylvania | LIPID NANOPARTICLE (LNP) COMPOSITIONS AND METHODS OF USE THEREOF |
| US20250043269A1 (en) | 2021-11-03 | 2025-02-06 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | Precise Genome Editing Using Retrons |
| WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
| WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| WO2023183300A1 (en) * | 2022-03-22 | 2023-09-28 | The Children's Medical Center Corporation | Compositions and methods for prevention and treatment of genetic disease |
| CA3255619A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS |
| EP4519243A4 (en) * | 2022-05-04 | 2026-04-22 | Univ Pennsylvania | Siloxane-based lipids, lipid nanoparticle compositions comprising them, and their methods of use for targeted administration |
| WO2023230587A2 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| JP2025525569A (ja) | 2022-07-18 | 2025-08-05 | レナゲード セラピューティクス マネージメント インコーポレイテッド | 遺伝子編集成分、システム、及び使用方法 |
| WO2024026029A2 (en) * | 2022-07-27 | 2024-02-01 | Trustees Of Tufts College | Lipid nanoparticles for immunotherapy |
| AU2023329392A1 (en) | 2022-08-25 | 2025-02-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| WO2024192291A1 (en) | 2023-03-15 | 2024-09-19 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| EP4680595A2 (en) | 2023-03-15 | 2026-01-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
| WO2024206230A1 (en) * | 2023-03-24 | 2024-10-03 | Trustees Of Tufts College | Tissue targeting lipids and lipid nanoparticles |
| WO2024220609A1 (en) * | 2023-04-18 | 2024-10-24 | The Trustees Of The University Of Pennsylvania | Ionizable lipid compounds, lipid nanoparticles (lnps) comprising the same, and methods of use thereof for cell engineering |
| WO2025007148A1 (en) | 2023-06-30 | 2025-01-02 | Orna Therapeutics, Inc. | Polymer lipid nanoparticle compositions for delivering circular polynucleotides |
| WO2025008510A1 (en) * | 2023-07-06 | 2025-01-09 | Etherna Immunotherapies Nv | Ionizable lipids |
| IT202300015003A1 (it) * | 2023-07-18 | 2025-01-18 | Univ Degli Studi Di Salerno | Composizione e procedimento per la realizzazione di nano-carriers lipidici ed i relativi nano-carriers lipidici di uso biomedico |
| WO2025038494A1 (en) | 2023-08-11 | 2025-02-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation |
| EP4771154A2 (en) | 2023-09-01 | 2026-07-08 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| EP4784174A1 (en) * | 2023-09-28 | 2026-08-05 | Trustees of the University of Pennsylvania | Compositions and methods for targeting immune cells |
| WO2025075396A1 (ko) * | 2023-10-06 | 2025-04-10 | 한국과학기술연구원 | 타겟 핵산 검출물질이 담지된 지질 나노입자 및 이를 이용한 막융합 기반의 타겟 핵산 검출 방법 |
| WO2025081042A1 (en) | 2023-10-12 | 2025-04-17 | Renagade Therapeutics Management Inc. | Nickase-retron template-based precision editing system and methods of use |
| IL327927A (en) * | 2023-10-22 | 2026-06-01 | Tessera Therapeutics Inc | Lipid nanoparticles for delivery of therapeutic payloads to t cells |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| AU2024409393A1 (en) * | 2023-12-18 | 2026-07-09 | Nanovation Therapeutics Inc. | Lipid nanoparticles having non-polar lipids for nucleic acid delivery to the liver |
| AU2024409925A1 (en) | 2023-12-26 | 2026-08-06 | Emmune, Inc. | Systems for nucleic acid transfer |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
| WO2025166238A1 (en) | 2024-01-31 | 2025-08-07 | Orna Therapeutics, Inc. | Fast-shedding polyethylene glycol lipids |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025184476A1 (en) * | 2024-02-29 | 2025-09-04 | The Trustees Of The University Of Pennsylvania | Cationic degradable lipid compositions, lipid nanoparticles (lnps) comprising same, and methods of use thereof |
| WO2025252759A1 (en) | 2024-06-03 | 2025-12-11 | Bio-Sourcing | Transient expression by lipid nanoparticle formulations |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026015458A1 (en) * | 2024-07-08 | 2026-01-15 | Memorial Sloan-Kettering Cancer Center | Cells comprising non-hla restricted t cell receptors |
| WO2026071602A1 (ko) * | 2024-09-30 | 2026-04-02 | 한국과학기술연구원 | 면역세포 내 유전자 조작을 위한 신규한 지질나노입자 조성물 |
| WO2026095067A1 (ja) * | 2024-11-01 | 2026-05-07 | Agc株式会社 | 核酸送達用脂質ナノ粒子 |
| WO2026109722A1 (en) | 2024-11-21 | 2026-05-28 | Aldexchem Kft. | Advanced silicon-containing lipid nanoparticles for efficient human t cell transfection |
| WO2026122685A1 (en) | 2024-12-03 | 2026-06-11 | Orna Therapeutics, Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2026161895A1 (en) | 2025-01-27 | 2026-07-30 | Tune Therapeutics, Inc. | Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression |
| WO2026165530A1 (en) | 2025-02-03 | 2026-08-06 | Renagade Therapeutics Management Inc. | Hydrophilic polymer lipids for use in lipid nanoparticles |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010053572A2 (en) * | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| US9126966B2 (en) * | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
| EP3247328B1 (en) * | 2015-01-21 | 2026-01-07 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| RS63051B1 (sr) | 2015-12-22 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularnu isporuku agenasa |
| US20190241658A1 (en) * | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
| AU2017337073A1 (en) * | 2016-09-30 | 2019-04-18 | Baylor College Of Medicine | Antibody based gene therapy with tissue-directed expression |
| US20190314291A1 (en) * | 2018-01-30 | 2019-10-17 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
-
2020
- 2020-10-19 US US17/769,893 patent/US20220378700A1/en active Pending
- 2020-10-19 JP JP2022523023A patent/JP7744687B2/ja active Active
- 2020-10-19 EP EP20877617.9A patent/EP4045021A4/en active Pending
- 2020-10-19 CN CN202080088023.6A patent/CN114828837A/zh active Pending
- 2020-10-19 WO PCT/US2020/056255 patent/WO2021077067A1/en not_active Ceased
- 2020-10-19 KR KR1020227016631A patent/KR20220084366A/ko active Pending
- 2020-10-19 CA CA3155075A patent/CA3155075A1/en active Pending
- 2020-10-19 AU AU2020366519A patent/AU2020366519B2/en active Active
-
2025
- 2025-09-05 JP JP2025147778A patent/JP2025175052A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| RILEY, R. S. et al., "Delivery technologies for cancer immunotherapy", NATURE REVIEWS DRUG DISCOVERY, vol. 18, 31 March 2019 (2019-03-31), pages 175-196 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025175052A (ja) | 2025-11-28 |
| JP2022552008A (ja) | 2022-12-14 |
| EP4045021A4 (en) | 2024-02-21 |
| CA3155075A1 (en) | 2021-04-22 |
| WO2021077067A1 (en) | 2021-04-22 |
| JP7744687B2 (ja) | 2025-09-26 |
| US20220378700A1 (en) | 2022-12-01 |
| EP4045021A1 (en) | 2022-08-24 |
| KR20220084366A (ko) | 2022-06-21 |
| AU2020366519A1 (en) | 2022-05-26 |
| CN114828837A (zh) | 2022-07-29 |